The biotech company said it would initiate a Phase III trial of Ultomiris in Covid-19-related pneumonia and acute respiratory distress syndrome. The announcement comes nearly a month after it said it was exploring the use of Soliris, an older and related drug.

LEAVE A REPLY

Please enter your comment!
Please enter your name here